ARTICLE | Deals
Deals report: Merck buying Buffalo academic spinout to enhance ADCs
Plus more antibody-drug conjugate deals: Ipsen-Sutro, Merck KGaA-Caris
April 9, 2024 12:18 AM UTC
Merck is acquiring a University at Buffalo spinout for up to $208 million to improve the performance of antibody-drug conjugates in its pipeline.
An announcement by the State University of New York institution did not include the upfront payment, but said the takeout of Abceutics Inc. by Merck & Co. Inc. (NYSE:MRK) includes milestones tied to “the progress of candidates.”...
BCIQ Company Profiles
BCIQ Target Profiles